StreetInsider.com News Articles

Form 4 Bicara Therapeutics Inc. For: Jul 10 Filed by: Mazumdar Claire

Tue, 14 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260714/26768532.html

Form 4 Bicara Therapeutics Inc. For: Jul 10 Filed by: Mazumdar Claire

Tue, 14 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260714/26768532.html

Form 4 Bicara Therapeutics Inc. For: Jul 08 Filed by: Cohlhepp Ryan

Fri, 10 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260710/26757438.html

Form 4 Bicara Therapeutics Inc. For: Jul 08 Filed by: Cohlhepp Ryan

Fri, 10 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260710/26757438.html

Form 4 Bicara Therapeutics Inc. For: Jul 08 Filed by: Hyep Ivan

Fri, 10 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260710/26757439.html

Form 4 Bicara Therapeutics Inc. For: Jul 08 Filed by: Hyep Ivan

Fri, 10 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260710/26757439.html

Form 144 Bicara Therapeutics Inc. Filed by: Mazumdar Claire

Fri, 10 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260710/26757337.html

Form 144 Bicara Therapeutics Inc. Filed by: Mazumdar Claire

Fri, 10 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260710/26757337.html

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Wed, 08 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260708/26747943.html

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Wed, 08 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260708/26747943.html

Form 144 Bicara Therapeutics Inc. Filed by: Cohlhepp Ryan

Wed, 08 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260708/26747659.html

Form 144 Bicara Therapeutics Inc. Filed by: Cohlhepp Ryan

Wed, 08 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260708/26747659.html

Form 144 Bicara Therapeutics Inc. Filed by: Hyep Ivan

Wed, 08 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260708/26747573.html

Form 144 Bicara Therapeutics Inc. Filed by: Hyep Ivan

Wed, 08 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260708/26747573.html

Form 144 Bicara Therapeutics Inc. Filed by: Meisner Lara

Tue, 07 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260707/26741836.html

Form 144 Bicara Therapeutics Inc. Filed by: Meisner Lara

Tue, 07 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260707/26741836.html

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 08:30:00 -0400

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment.

The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 08:30:00 -0400

Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens

Wed, 01 Jul 2026 04:49:49 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $31.00 price target on Bicara Therapeutics Inc (NASDAQ: BCAX).

The analyst commented, "Beyond the headline HNSCC indication, Bicara is also exploring ficera in late line MSS+ mCRC, where EGFRdirected antibodies like cetuximab have shown benefit. The company is targeting late-line microsatellite stable (MSS) KRAS/RAS/BRAF wt CRC population, combining ficera’s TGF-β and EGFR inhibition with PD- (L)1 blockade to target complementary drivers of metastasis and resistance. Although Bicara has presented preclinical data on ficera in CRC, this will be the first clinical presentation dedicated to an indication that could significantly expand the

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Thu, 25 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260625/26692360.html

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Thu, 25 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260625/26692360.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Shah Rajeev M.

Wed, 10 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260610/26630531.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Shah Rajeev M.

Wed, 10 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260610/26630531.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Haviland Kate

Wed, 10 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260610/26630423.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Haviland Kate

Wed, 10 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260610/26630423.html